Healthcare >> Analyst Interviews >> May 6, 2002

Canadian Biotechnology Stocks: Claude Camire – Dundee Securities

CLAUDE CAMIR has had a 20-year career covering the pharmaceutical, biotech and medical devices industries, including the last four years as a healthcare analyst. His coverage of the sector includes biotech, service and manufacturing companies in Canada and the US. He has worked in senior and managerial positions covering marketing, finance and business development activities for Abbott Laboratories, Aventis (Rhone- Poulenc Rorer) and Biochem Pharma. He has been involved extensively in technology valuation, financing and mergers and acquisitions in North America and Europe. He has received his B. Comm (Finance/Accounting) degree from the University of Sherbrooke. He is currently enrolled in the MBA program at the Universit_ du Qu_bec in Montreal and the CFA program level 2 (exam scheduled for June 2003). Profile
TWST: To begin, what differentiates Canadian biotech from its

North American counterpart?

Mr. Camir: I think nothing really differentiates the two

countries' biotech efforts. I think we're